19.94
Relay Therapeutics Inc (RLAY) 最新ニュース
Relay Therapeutics Inc (RLAY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Relay Therapeutics Inc (RLAY) Institutional Confidence - TradingKey
Relay Therapeutics Inc (RLAY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Relay Therapeutics Inc (RLAY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RLAY|Relay Therapeutics Inc|Price:18.440|Chg%:-0.650 - TradingKey
Relay Therapeutics Inc (RLAY) Cash Flow - TradingKey
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
TradingKey - TradingKey
Relay Therapeutics Inc (RLAY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Relay Therapeutics Inc (RLAY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Relay Therapeutics Inc (RLAY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Is RLAY Stock Rising Today? - Stocktwits
Relay Therapeutics (RLAY) insider plans sale of 30,000 shares after option exercise - Stock Titan
RLAY Maintained by Goldman Sachs -- Price Target Raised to $31 - GuruFocus
Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Relay Therapeutics stock trades around recent lows as cash burn and pipeline data shape the outlook - Ad-hoc-news.de
Relay Therapeutics, Inc. SEC Filing (Jul 20, 2026) - Stock Titan
Certain Stock Options of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Certain Common Stock of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Canaccord initiates Relay Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Relay Therapeutics (RLAY) Edges Higher as Stock Tests Key Resistance at $20.68High Volume Stocks - dars.gov.et
Canaccord initiates Relay Therapeutics stock with buy rating - Investing.com
RLAY Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus
CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29 - Moomoo
Relay Therapeutics Inc. (RLAY) Q1 2026 Earnings: EPS Miss Weighs on Shares as Pipeline Progress Waits - Bölüm Sonu Canavarı
Relay Therapeutics president sells $162,028 in company stock - Investing.com UK
Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing - Moomoo
Insider Sell Alert: Donald Bergstrom Sells Shares of Relay Thera - GuruFocus
Form 4 Relay Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Relay Therapeutics president and CEO Sanjiv Patel sells $943,736 in stock - Investing.com Nigeria
Relay Therapeutics (RLAY) R&D chief sells 8,660 shares in 10b5-1 trade - Stock Titan
Relay Therapeutics CFO Thomas Catinazzo sells $331,130 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics Insider Sold Shares Worth $943,736, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics president sells $162,028 in company stock By Investing.com - Investing.com UK
Relay Therapeutics (RLAY) CEO trades shares, keeps over 615K direct holdings - Stock Titan
CFO at Relay Therapeutics (RLAY) sells shares under Rule 10b5-1 plan - Stock Titan
Why Relay Therapeutics (RLAY) Is Up 5.5% After Broad Russell Growth Index Inclusion And What's Next - simplywall.st
JPMorgan initiates Relay Therapeutics stock coverage with overweight rating By Investing.com - Investing.com Nigeria
JPMorgan initiates Relay Therapeutics stock coverage with overweight rating - Investing.com
Form 144 RELAY THERAPEUTICS INC For: 7 July By Investing.com - Investing.com Nigeria
Relay Therapeutics stock hits 52-week high at 19.97 USD By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week high at 19.97 USD - Investing.com
Enterprise value to revenue forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
大文字化:
|
ボリューム (24 時間):